Tempest Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 0.4955 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 8.20M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agr...